ALK and non-small cell lung carcinoma: Similarly, Solomon et al. conducted a combinatorial study in which avelumab, axitinib, and palbociclib were administered to advanced NSCLC patients who had previously undergone at least two lines of treatment and showed no changes in EGFR, ALK, or ROS1.